
Belite Bio, Inc (BLTE)
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Market Cap
$1.9B
Revenue
$0
P/E Ratio
N/A
P/B Ratio
13.21
D/E Ratio
0.00
Dividend Yield
0.00%
PEG Ratio
63.44
Net Income
-$36M
Net Profit Margin
0.00%
Beta
-1.445
Gross Margin
0.00%
R/S Growth
0.00
52W Low
$0.00
52W High
$0.00
Updated: June 30 at 18:46:39